[go: up one dir, main page]

IL148045A0 - Androgen receptor modulator compounds and methods - Google Patents

Androgen receptor modulator compounds and methods

Info

Publication number
IL148045A0
IL148045A0 IL14804500A IL14804500A IL148045A0 IL 148045 A0 IL148045 A0 IL 148045A0 IL 14804500 A IL14804500 A IL 14804500A IL 14804500 A IL14804500 A IL 14804500A IL 148045 A0 IL148045 A0 IL 148045A0
Authority
IL
Israel
Prior art keywords
methods
androgen receptor
receptor modulator
modulator compounds
compounds
Prior art date
Application number
IL14804500A
Other languages
English (en)
Original Assignee
Ligand Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ligand Pharm Inc filed Critical Ligand Pharm Inc
Publication of IL148045A0 publication Critical patent/IL148045A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL14804500A 1999-08-27 2000-08-25 Androgen receptor modulator compounds and methods IL148045A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15098899P 1999-08-27 1999-08-27
PCT/US2000/023520 WO2001016139A1 (en) 1999-08-27 2000-08-25 Androgen receptor modulator compounds and methods

Publications (1)

Publication Number Publication Date
IL148045A0 true IL148045A0 (en) 2002-09-12

Family

ID=22536855

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14804500A IL148045A0 (en) 1999-08-27 2000-08-25 Androgen receptor modulator compounds and methods

Country Status (21)

Country Link
US (3) US6462038B1 (es)
EP (1) EP1212330B1 (es)
JP (1) JP2003508402A (es)
KR (1) KR20020038741A (es)
CN (1) CN1391576A (es)
AT (1) ATE323709T1 (es)
AU (1) AU778655B2 (es)
BG (1) BG106550A (es)
BR (1) BR0013597A (es)
CA (1) CA2383077A1 (es)
CZ (1) CZ2002711A3 (es)
DE (1) DE60027443D1 (es)
HU (1) HUP0202814A3 (es)
IL (1) IL148045A0 (es)
MX (1) MXPA02002032A (es)
NO (1) NO20020913L (es)
PL (1) PL353792A1 (es)
SK (1) SK2732002A3 (es)
TR (1) TR200200507T2 (es)
WO (1) WO2001016139A1 (es)
ZA (1) ZA200201056B (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
KR20020038741A (ko) * 1999-08-27 2002-05-23 윌리암 엘. 레스페스 안드로겐 수용체 조절 화합물 및 방법
US7001911B2 (en) 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
BR0111298A (pt) 2000-06-28 2005-05-10 Bristol Myers Squibb Co Moduladores seletivos dos receptores de andrógenos e métodos para identificação, projeto e uso dos mesmos
US20040077605A1 (en) 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US6953679B2 (en) 2000-09-19 2005-10-11 Bristol-Myers Squibb Company Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
US7214690B2 (en) * 2001-02-23 2007-05-08 Ligand Pharmaceuticals Incorporated Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods
US7026484B2 (en) 2001-02-23 2006-04-11 Ligand Pharmaceuticals Incorporated Tricyclic androgen receptor modulator compounds and methods
EP1414795A4 (en) 2001-07-31 2006-03-01 Bristol Myers Squibb Co BICYCLIC MODULATORS OF THE FUNCTION OF THE ANDROGEN RECEPTOR
AU2002364082A1 (en) 2001-12-19 2003-07-09 Bristol-Myers Squibb Company Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function
CN1315836C (zh) * 2002-04-26 2007-05-16 奥索-麦克尼尔药品公司 用作雄激素受体调节剂的2－(喹诺酮基)－稠合杂环
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
CN1665510A (zh) * 2002-06-25 2005-09-07 惠氏公司 作为pr调节剂的环硫代氨基甲酸酯衍生物的衍生物和其用于治疗皮肤病的用途
EP1567487A4 (en) 2002-11-15 2005-11-16 Bristol Myers Squibb Co OPEN-CHAINED, PROLYL-FROSTED MODULATORS OF ANDROGEN RECEPTOR FUNCTION
CA2511491A1 (en) 2003-01-17 2004-08-05 Warner-Lambert Company Llc Androgen receptor antagonists
BRPI0406778A (pt) 2003-01-17 2006-01-17 Warner Lambert Co Antagonistas de receptores de androgênio
CA2514244A1 (en) 2003-02-11 2004-08-26 Warner-Lambert Company Llc Benzyl urea and thiourea derivatives useful as androgen antagonists
BRPI0407354A (pt) 2003-02-11 2006-01-10 Warner Lambert Co Derivados de uréia e tiouréia
US7009052B2 (en) 2003-03-20 2006-03-07 Warner Lambert Company Llc Sulfonamide derivatives
US7098340B2 (en) 2003-05-14 2006-08-29 Warner Lambert Company Llc Benzyl sulfonamide derivatives
WO2005000795A2 (en) * 2003-06-10 2005-01-06 Smithkline Beecham Corporation Aniline derivatived androgen-, glucocorticoid-, mineralcorticoid- and progesterone- receptor modulators
CA2536349A1 (en) * 2003-08-22 2005-03-03 Ligand Pharmaceuticals Incorporated 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds
CA2546601A1 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
WO2005063494A1 (ja) * 2003-12-26 2005-07-14 Mitsubishi Chemical Corporation 光学記録媒体および色素
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US8519158B2 (en) 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
US7282507B2 (en) * 2004-05-03 2007-10-16 Janssen Pharmaceutica N.V. Indole derivatives as selective androgen receptor modulators (SARMS)
CN1980934B (zh) * 2004-05-03 2011-10-26 詹森药业有限公司 作为选择性雄激素受体调节剂（sarms）的新的吲哚衍生物
JP4874965B2 (ja) * 2004-07-08 2012-02-15 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー アンドロゲン調節剤
US7280723B2 (en) * 2005-05-06 2007-10-09 Schott Corporation Illumination assembly including a rigid light-guiding element incorporating a numerical-aperture alteration taper
CN101137655A (zh) 2005-06-17 2008-03-05 配体药物公司 雄激素受体调节剂化合物和方法
US7645885B2 (en) * 2005-08-26 2010-01-12 The Regents Of The University Of California Non-steroidal antiandrogens
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
ATE547394T1 (de) 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
ES2413504T3 (es) 2007-12-21 2013-07-16 Ligand Pharmaceuticals Inc. Moduladores selectivos del receptor de andrógeno (SARM) y usos de los mismos
EP2130831A1 (en) 2008-06-06 2009-12-09 InterMed Discovery GmbH CDC25 inhibitors
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
KR20210018291A (ko) 2018-05-14 2021-02-17 누베이션 바이오 인크. 항암 핵 호르몬 수용체-표적화 화합물
CN108659219B (zh) * 2018-06-08 2021-02-09 扬州大学 一种聚苯胺的制备方法
JP2022529341A (ja) 2019-04-19 2022-06-21 リガンド・ファーマシューティカルズ・インコーポレイテッド 化合物の結晶形、および化合物の結晶形を生成する方法
CN113811333B (zh) 2019-05-14 2024-03-12 诺维逊生物股份有限公司 靶向抗癌核激素受体的化合物
US11952349B2 (en) 2019-11-13 2024-04-09 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
MX2023011241A (es) 2021-03-23 2023-10-03 Nuvation Bio Inc Compuestos dirigidos a receptores de hormonas nucleares contra el cancer.
WO2022235585A1 (en) 2021-05-03 2022-11-10 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH590274A5 (es) 1970-03-16 1977-07-29 Hoffmann La Roche
GB1379387A (en) 1970-12-11 1975-01-02 Agfa Gevaert Photoconductive recording materials
US3979394A (en) 1970-12-11 1976-09-07 Agfa-Gevaert N.V. Duplo quinoline compounds
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
GB1400993A (en) 1971-11-10 1975-07-16 Agfa Gevaert Electrophotographic material
BE795696A (nl) 1972-02-28 1973-08-21 Agfa Gevaert Nv Voor warmte gevoelige materialen
US3936461A (en) * 1973-09-24 1976-02-03 Warner-Lambert Company Substituted 4-benzylquinolines
US3993656A (en) 1974-11-19 1976-11-23 Merck & Co., Inc. 1,8-Naphthyridine compounds
IE43079B1 (en) * 1975-03-20 1980-12-17 Ici Ltd Quinolone derivatives
US4138490A (en) 1975-03-20 1979-02-06 Imperial Chemical Industries Limited Analgesic compositions containing 1,2-dihydro-2-oxoquinol-4-ylpropionic acid derivatives
SU555119A1 (ru) 1975-05-19 1977-04-25 Предприятие П/Я Г-4913 Вулканизуема резинова смесь на основе полиизопренового каучука
LU77254A1 (es) 1977-05-04 1979-01-18
US4579134A (en) * 1977-09-08 1986-04-01 The Bridgeport Metal Goods Manufacturing Co. Lipstick container
US4326055A (en) 1977-12-22 1982-04-20 Hoffmann-La Roche Inc. Stilbene derivatives
JPS54154797A (en) * 1978-05-25 1979-12-06 Eisai Co Ltd Benzimidazoquinolizine derivative and antibacterials comprising it
US4234589A (en) 1979-09-24 1980-11-18 E. R. Squibb & Sons, Inc. Imidazolylethoxymethyl derivatives of 1,3-dioxolo quinolines
JPS5777676A (en) 1980-10-31 1982-05-15 Otsuka Pharmaceut Co Ltd Carbostyril derivative
DE3202100A1 (de) 1982-01-23 1983-08-04 Basf Ag, 6700 Ludwigshafen Substituierte benzoesaeure-4-hydroxyanilide, ihre herstellung und diese enthaltende pharmazeutische zubereitungen
US4534979A (en) 1982-06-28 1985-08-13 Usv Pharmaceutical Corp. Polyene compounds useful in the treatment of psoriasis and allergic responses
US4427654A (en) 1982-07-27 1984-01-24 University Of Delaware Wound healing compositions and formulations
US4505852A (en) 1982-11-29 1985-03-19 Enzyme Systems Products 7-Amino-4-trifluoromethylquinolone derived substrates and method for determining enzymes and inhibitors
US4539134A (en) 1982-12-02 1985-09-03 Halliburton Company Methods and cleaning compositions for removing organic materials from metallic surfaces
JPS6056985A (ja) * 1983-09-08 1985-04-02 Sankyo Co Ltd クマリン誘導体
US4710507A (en) 1983-12-22 1987-12-01 Pfizer Inc. Quinolone inotropic agents
PT80533B (en) 1984-05-29 1987-04-06 Pfizer Process for preparing quinolone inotropic agents
FR2569689B1 (fr) 1984-09-05 1990-11-16 Oreal Nouveaux derives du benzonorbornene, leurs procedes de preparation et compositions medicamenteuse et cosmetique les contenant
DE3434944A1 (de) 1984-09-22 1986-04-03 Basf Ag, 6700 Ludwigshafen L-substituierte tetralinderivate, ihre herstellung und verwendung
FR2580277B1 (fr) 1985-04-15 1988-06-10 Oreal Nouveaux derives naphtaleniques a action retinoique, le ur procede de preparation et compositions medicamenteuse et cosmetique les contenant
LU86022A1 (fr) 1985-07-25 1987-02-04 Cird Derives aromatiques polycyliques,leur procede de preparation et leur application dans les domaines pharmaceutique et cosmetique
JPS62215581A (ja) 1986-03-18 1987-09-22 Koichi Shiyudo フラボンカルボン酸誘導体
FR2601670B1 (fr) 1986-07-17 1988-10-07 Cird Nouveaux derives bicycliques aromatiques, leur procede de preparation et leur utilisation en medecine humaine et veterinaire et en cosmetique
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
FR2605626B1 (fr) 1986-10-27 1989-06-02 Oreal Nouveaux derives aromatiques bicycliques, leur procede de preparation et leur utilisation en cosmetique et en medecine humaine et veterinaire
US5081242A (en) 1986-12-22 1992-01-14 Ortho Pharmaceutical Corporation 6-benzoxazinyl- and 6-benzothiazinyl 2,3,4,5-tetrahydropyridazin-3-ones
GB8630702D0 (en) 1986-12-23 1987-02-04 Wellcome Found Quinoline compound
FR2614618B1 (fr) 1987-04-30 1989-07-07 Cird Derives heterocycliques polycycliques, leur procede de preparation et leur utilisation en medecine humaine et veterinaire
EP0303418A3 (en) 1987-08-11 1990-11-07 Smithkline Beecham Laboratoires Pharmaceutiques Substituted indolones, useful in the treatment of heart or asthmatic diseases
LU87040A1 (fr) 1987-11-04 1989-06-14 Oreal Esters aromatiques polycycliques d'antibiotiques macrolidiques et lincosamidiques,leur procede de preparation et compositions pharmaceutiques et cosmetiques les contenant
US4981784A (en) 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
WO1989007441A1 (en) 1988-02-10 1989-08-24 The Regents Of The University Of California 6-amino-1,2-benzopyrone antitumorigenic agents and method
DE3810706A1 (de) 1988-03-25 1989-10-05 Schering Ag Substituierte cumarinderivate, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider wirkung
EP0347960B1 (en) 1988-06-23 1994-07-06 Agfa-Gevaert N.V. Photosensitive recording material suited for use in electrophotography
GB8820174D0 (en) 1988-08-25 1988-09-28 Wellcome Found Quinoline compound
US5108486A (en) * 1990-02-09 1992-04-28 Kanagawa Chemical Laboratory, Ltd. Herbicidal substituted-phenyl-1,2,4-triazol-5(1H)-thiones and -ones
US5091528A (en) 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
DE4036779A1 (de) 1990-11-17 1992-05-21 Basf Ag Verwendung von arylpolyencarbonsaeuren und ihren derivaten als lichtschutzmittel in kosmetischen zubereitungen
JPH0570464A (ja) * 1991-02-18 1993-03-23 Yamanouchi Pharmaceut Co Ltd オキサジノベンズアゾール化合物
US5147844A (en) 1991-06-14 1992-09-15 Eastman Kodak Company Mixture on cyan and yellow dyes to form a green hue for color filter array element
FR2683818B1 (fr) 1991-11-14 1993-12-31 Adir Cie Nouveaux derives de 3-sulfonylamino-2-(1h)-quinoleinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
PT637297E (pt) 1992-04-22 2001-01-31 Ligand Pharm Inc Compostos com selectividade para os receptores de retinoide x
CA2093577C (en) 1992-05-07 2006-01-03 Michael Klaus Alkyl or alkoxy substituted s-heterocyclic retinoids
US5391569A (en) 1992-09-29 1995-02-21 Adir Et Compagnie New chromene compounds having a triene side chain
EP0671005A1 (en) 1992-11-25 1995-09-13 La Jolla Cancer Research Foundation Rxr homodimer formation and bridged bicyclic aromatic compounds and their use in modulating gene expression
WO1994015901A1 (en) 1993-01-11 1994-07-21 Ligand Pharmaceuticals Inc. Compounds having selectivity for retinoid x receptors
KR100306855B1 (ko) 1993-01-11 2001-11-30 윌리암 엘. 레스페스 레티노이드x수용체에대한선택성을갖는화합물
US5455265A (en) 1993-02-11 1995-10-03 Allergan, Inc. Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
US5399586A (en) 1993-03-11 1995-03-21 Allergan, Inc. Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity
US5677336A (en) * 1993-10-21 1997-10-14 Ligand Pharmaceuticals Incorporated Non-steroid androgen receptor antagonist compounds and methods
WO1995024394A1 (en) 1994-03-08 1995-09-14 Takeda Chemical Industries, Ltd. Quinoline or quinazoline derivatives as anti-inflammatory agents, in particular for treating arthritis
FR2719041B1 (fr) 1994-04-26 1996-05-31 Cird Galderma Nouveaux composés polyéniques, compositions pharmaceutiques et cosmétiques les contenant et utilisations.
US5801253A (en) 1994-08-10 1998-09-01 Hoffmann-La Roche Inc. Retinoic acid X-receptor ligands
US5977125A (en) 1994-10-31 1999-11-02 Eisai Co., Ltd. Mono-or polyenic carboxylic acid derivatives
IL116259A (en) 1994-12-19 2000-07-16 American Cyanamid Co Analogs of 9-cis retinoic acid and their use
US5968908A (en) 1994-12-19 1999-10-19 American Cyanamid Company Restricted 9-cis retinoids
US5688808A (en) 1994-12-22 1997-11-18 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
US6696459B1 (en) * 1994-12-22 2004-02-24 Ligand Pharmaceuticals Inc. Steroid receptor modulator compounds and methods
NZ300739A (en) 1994-12-22 2000-05-26 Ligand Pharm Inc Steroid receptor modulator compounds
US5721103A (en) 1994-12-30 1998-02-24 Ligand Pharmaceuticals Incorporated Trienoic retinoid compounds and methods
WO1996020913A1 (en) 1994-12-30 1996-07-11 Ligand Pharmaceuticals Incorporated Novel trienoic retinoid compounds and methods
EP0835258B1 (fr) * 1995-06-21 2002-09-25 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Nouveaux analogues de la camptothecine, des procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
WO1997007120A1 (en) * 1995-08-11 1997-02-27 Smithkline Beecham Plc Biphenyl(thio)amide and biphenylethan(thi)one derivatives, their preparation and their use as 5-ht1d receptor antagonists
US5776699A (en) 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
CA2233888A1 (en) 1995-10-06 1997-04-10 Ligand Pharmaceuticals Incorporated Dimer-selective rxr modulators and methods for their use
ATE209207T1 (de) * 1996-06-27 2001-12-15 Ligand Pharm Inc Androgen rezeptor modulator verbindungen und verfahren
US6017924A (en) * 1996-06-27 2000-01-25 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
FR2752837B1 (fr) 1996-09-02 1999-11-12 Cird Galderma Nouveaux composes modulateurs des recepteurs hormonaux, les compositions les comprenant et leur utilisation en therapie
JP2858002B2 (ja) * 1997-01-06 1999-02-17 大塚製薬株式会社 医薬組成物
JP3704471B2 (ja) 1997-11-12 2005-10-12 エフ．ホフマン−ラ ロシュ アーゲー レチノイド拮抗薬を用いるヘルパーｔ細胞媒介性免疫疾患の処置
US6001846A (en) * 1998-02-17 1999-12-14 Ligand Pharmaceuticals Incorporated Process for the preparation of 1,2-dihydroquinolines
JPH11242304A (ja) * 1998-02-26 1999-09-07 Konica Corp 熱現像感光材料
EP1056775B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
EP1077919A1 (en) 1998-05-11 2001-02-28 Novo Nordisk A/S New compounds, their preparation and use
US6093826A (en) * 1998-06-08 2000-07-25 Ligand Pharmaceuticals Incorporated Process for the preparation of C(5)-substituted 1,2-dihydro-5H-chromeno[3,4-f] quinolines
US6147224A (en) 1998-10-01 2000-11-14 Allergan Sales, Inc. 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
WO2000053562A1 (en) 1999-03-08 2000-09-14 Basilea Pharmaceutica Ag Retinoid antagonists and use thereof
AT407876B (de) 1999-04-30 2001-07-25 Georg Dr Uray Lumineszierende 4-trifluormethyl-2-chinolinone mit langwelliger uv-absorption und ihre verwendung
US6566372B1 (en) * 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US6667313B1 (en) * 1999-08-27 2003-12-23 Ligand Pharmaceuticals Inc. 8-substituted-6-triflouromethyl-9-pyrido [3,2-G] quinoline compounds as androgen receptor modulators
KR20020038741A (ko) * 1999-08-27 2002-05-23 윌리암 엘. 레스페스 안드로겐 수용체 조절 화합물 및 방법
US6172241B1 (en) * 1999-10-15 2001-01-09 Ligand Pharmaceuticals Incorporated Process for the preparation of 1,2-dihydroquinolines
US7214690B2 (en) * 2001-02-23 2007-05-08 Ligand Pharmaceuticals Incorporated Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods
US7026484B2 (en) * 2001-02-23 2006-04-11 Ligand Pharmaceuticals Incorporated Tricyclic androgen receptor modulator compounds and methods
EP1414795A4 (en) * 2001-07-31 2006-03-01 Bristol Myers Squibb Co BICYCLIC MODULATORS OF THE FUNCTION OF THE ANDROGEN RECEPTOR

Also Published As

Publication number Publication date
CN1391576A (zh) 2003-01-15
ATE323709T1 (de) 2006-05-15
DE60027443D1 (de) 2006-05-24
WO2001016139A1 (en) 2001-03-08
BR0013597A (pt) 2002-07-16
CA2383077A1 (en) 2001-03-08
HUP0202814A3 (en) 2003-11-28
NO20020913L (no) 2002-04-29
NO20020913D0 (no) 2002-02-25
AU6941400A (en) 2001-03-26
SK2732002A3 (en) 2002-07-02
US20070167445A1 (en) 2007-07-19
WO2001016139A9 (en) 2002-09-19
EP1212330A1 (en) 2002-06-12
HUP0202814A2 (hu) 2002-12-28
KR20020038741A (ko) 2002-05-23
JP2003508402A (ja) 2003-03-04
US6462038B1 (en) 2002-10-08
EP1212330B1 (en) 2006-04-19
ZA200201056B (en) 2003-07-30
MXPA02002032A (es) 2003-05-19
CZ2002711A3 (cs) 2003-11-12
BG106550A (en) 2002-10-31
AU778655B2 (en) 2004-12-16
TR200200507T2 (tr) 2002-10-21
PL353792A1 (en) 2003-12-01
US20030186970A1 (en) 2003-10-02

Similar Documents

Publication Publication Date Title
IL148045A0 (en) Androgen receptor modulator compounds and methods
BG106539A (en) Bicyclic androgen and progesterone receptor modulator compounds and methods
WO2001016133A3 (en) 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators
AU2003228283A1 (en) Quinazolinone modulators of nuclear receptors
AU3508497A (en) Androgen receptor modulator compounds and methods
HK1043788A1 (zh) 四環黃體酮受體調節劑化合物及方法
AU4597796A (en) Steroid receptor modulator compounds and methods
CR6478A (es) Moduladores del receptor glucocorticoide
AU2002367060A1 (en) Heterocyclic modulators of nuclear receptors
IL184642A0 (en) Process for the preparation of non-steroidal glucocorticoid receptor modulators
DE69819726D1 (de) Selektive analoge der thyroidhormone
WO2002066475A3 (en) Tricyclic androgen receptor modulator compounds
NO985242D0 (no) Tetrahydroisokinolin-derivater som modulatorer for dopamin D3-reseptorer
BG105761A (en) Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
MXPA03001610A (es) Derivados de acido oxazolil-arilpropionico y su uso como agonistas de los receptores activados por proliferadores de peroxisomas.
BR0011741A (pt) Compostos de organossilila tendo atividade de modulação do receptor de hormÈnio nuclear
WO2005009104A3 (en) Benzoic and phenyl acetic acid derivatives as hnf-4 modulators
HK1055058A2 (en) 5-CYCLOALKENYL 5H-CHROMENO[3,4-f]QUINOLINE DERIVATIVES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS
AU1356299A (en) New compounds which are p2-purinoceptor 7-transmembrane (tm) g-protein coupled receptor antagonists
HK1055059A2 (en) 5-SUBSTITUTED 7,9-DIFLUORO-5H-CHROMENO[3,4-f]QUINOLINE COMPOUNDS AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS
WO2005010202A3 (en) PHENYL ACETIC ACID DERIVATIVES AS HEPATOCYTE NUCLEAR FACTOR 4α (HNF-4α) MODULATOR COMPOUNDS
NZ334622A (en) Phenozyethylamine derivatives, method of preparation, application as medicine and pharmaceutical compositions containing same which have high affinity for 5-HT1A receptors and can be used to inhibit gastric acid secretion or as an antiemetic